WORCESTER, Mass., Jan. 7, 2010 (GLOBE NEWSWIRE) -- When examining the science at Generex, one need not look any further than the treatment of diabetes to understand the vast potential of its proprietary drug delivery system and its flagship buccal insulin spray product, Generex Oral-lyn(TM). While I believe the true value of this drug delivery system is largely overlooked, it is easy to focus on its use for the treatment of Type 1 and Type 2 diabetes mellitus. In the United States alone, the American Diabetes Association estimates that 7.8% of the population (approximately 24 million people) has some form of diabetes. Additionally, there are over 1.6 million new cases of diabetes diagnosed each year. It is the seventh leading cause of death in the U.S. and leads to a host of related illnesses, including heart disease. The annual direct medical cost of diabetes in the U.S. was estimated to be over $116 billion in 2007.
